Our AstraZeneca (NASDAQ:AZN | AZN Price Prediction) call comes one day after the British drugmaker reported Q1 2026 revenue of $15.29 billion, up 13% year over year, and reaffirmed full-year guidance.
With shares at $185.20, the stock has cooled from its 52-week high of $210.50. Our 24/7 Wall St. price target for AstraZeneca is $227.39, implying 22.78% upside over the next 12 months. We rate AZN a buy with high confidence (90%).
24/7 Wall St. Price Target Summary
| Metric | Value |
|---|---|
| Current Price | $185.20 |
| 24/7 Wall St. Price Target | $227.39 |
| Upside | 22.78% |
| Recommendation | BUY |
| Confidence Level | 90% |
A Catalyst-Rich Quarter Met With a Pullback
AZN is down 4.93% over the past week and 4.48% over the past month, but still up 32.76% over one year.
Q1 oncology led, driven by Imfinzi at $1.69 billion (up 34%) and Enhertu at $831 million (up 40%). Core EPS of $2.58 rose only 4% as a higher core tax rate of 21% (vs. 16% prior year) compressed the bottom line.
Management reaffirmed FY2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth at CER, alongside a long-term ambition of $80 billion in revenue by 2030.
The Case for $235+
Bulls point to unprecedented pipeline cadence. AstraZeneca expects more than 20 Phase III readouts in 2026, and Q1 delivered four positive readouts, including tozorakimab hitting primary endpoints in three Phase III COPD trials and Imfinzi EMERALD-3 in HCC.
DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence for Enhertu. CEO Pascal Soriot framed the moment plainly: “We are advancing through our catalyst-rich period.”
The Wall Street consensus target of $223.89, with 2 Strong Buy and 6 Buy ratings, reflects this conviction. Guggenheim raised its target ahead of Q1. In the bull case, AZN reaches $236.65 by April 2027.
The Risks Worth Watching
The bear case centers on patent erosion and pricing pressure. Brilinta fell 65% in Q1 on generic competition, Soliris faces biosimilar pressure, and Forxiga patents were invalidated in the UK. Net debt rose to $25.9 billion, and Medicare Part D redesign plus China VBP implementation weigh on key franchises.
The Ceralasertib LATIFY Phase III failure is a reminder that not every readout lands. Bulls counter that the higher tax rate is a normalization from prior-year settlements, and the $50 billion US manufacturing and R&D investment through 2030 positions AstraZeneca for tariff resilience. Our bear case lands at $194.28, only modest downside.
Our Take
The 24/7 Wall St. price target of $227.39 reflects a buy rating at 90% confidence. The combination of 16 blockbuster franchises, a low beta of 0.28, and a forward P/E of 18x against double-digit Core EPS growth tips the scale.
The thesis holds if oncology momentum and the 2026 readout cadence translate into the $80 billion 2030 ambition. It weakens if Medicare pricing pressure or further patent setbacks reaccelerate. On balance, the risk-reward favors accumulation.
AstraZeneca Price Prediction 2026-2030
Here is where our 24/7 Wall St. price target model projects AZN could trade in the coming years, assuming current growth and pipeline execution hold.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $213 |
| 2027 | $240 |
| 2028 | $273 |
| 2029 | $305 |
| 2030 | $340 |
These projections assume AstraZeneca executes against its $80 billion 2030 revenue ambition and that the over 100 ongoing Phase III studies deliver steady approvals. Significant upside or downside could result from late-decade patent cliffs on Tagrisso and Farxiga, or from the pace of US drug-pricing reform.
Top Gaining Stocks
Top Losing Stocks